Fondaparinux

Trade names

ARIXTRA

Actions

• Direct factor Xa inhibitor

Route of Administration

Subcutaneous

Bioavailability

100%

Plasma protein binding

94%

Time to peak plasma concentration

2 h

Half-life

17 h

Duration of action

48–96 h

Metabolism

Not metabolized

Elimination

Renal

Recommended dose

DVT prophylaxis:

2.5 mg once daily

Renal impairment

In patients with creatinine clearance 20-50 ml/min the dose should be reduced to to 1.5 mg/day.

Fondaparinux is not recommended in patients with creatinine clearance <20 ml/min.

Discontinuation before invasive procedures

Stop at least 24 hours before an invasive procedure.